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MinireviewThe Platelet as a Model
for Chemical Genetics
the term forward chemical genetics has been used to
describe a strategy in which small molecules are used
much like mutations are used in classical genetics to
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are selected by high-throughput screening and their mo-
lecular targets identified. One advantage of a chemical
genetic approach is that once the target of a small mole-
cule is identified and its specificity proven, the moleculeChemical genetics is an emerging strategy in chemical
serves as a versatile probe that can cause conditionalbiology that promises to bring the power of true genet-
perturbations of diverse biological systems (from en-ics to mammalian systems and facilitate the transfer
zyme assays to cell cultures to mammalian organisms).of biological discoveries to therapeutics. The platelet
Furthermore, unlike a genetic mutation, such a probeis an anucleate cell with several features that render it
has immediate potential as a lead compound for a thera-suitable for chemical genetic analysis. This review ad-
peutic. Thus, the incentive to achieve widely applicabledresses the benefits and challenges of chemical genet-
chemical genetic strategies for analyzing varied com-ics using platelets as a model system.
plex biological systems is great. Yet, there are disadvan-
tages to this approach. Systematic strategies for identi-
fying the targets of active compounds and proving their
Chemical Genetics specificity have not become routine. For these reasons,
Several relatively recent advances from various fields biological systems must be carefully selected for this
have converged to create the opportunity to analyze approach. This article discusses the platelet as a cellular
complex biological systems using small molecules. model for chemical genetic analysis.
Sizeable small molecule libraries containing drug-like Pharmacology of Platelet Activation
compounds have become commercially available. In ad- Platelets constitute the primary cellular component of
dition, advances in diversity-oriented synthetic methods hemostasis in mammalian organisms. Their activity must
have lead to the creation of small molecule libraries with be exquisitely regulated since inadequate activity leads
enhanced diversity and complexity for probing biologi- to inappropriate bleeding and excessive activity leads
cal systems [1]. The adaptation of commonly used labo- to deleterious thrombosis. Several characteristics of the
ratory instruments to high-throughput formats has en- platelet have rendered it a popular model for studies
abled screening platforms capable of assaying large using small molecules. Perhaps the most important of
numbers of compounds for informative phenotypes [2]. these is the fact that platelets are anucleate. Thus, ge-
In addition, software has been developed that simplifies netic manipulation of platelets is difficult. Efforts to study
the analysis of the volumes of data derived from high- platelets using genetics have been limited largely to the
throughput assays. These advances have contributed study of platelets derived from transgenically altered
to unprecedented interest and activity in the field of murine models and nucleated cells transfected with
chemical biology. platelet proteins. A second reason human platelets have
The use of small molecules to perturb complex biolog- been used extensively for pharmacological studies is
ical systems in order to define the roles of specific pro- that, as circulating cells, they are easy to obtain. They
teins has been termed chemical genetics based on its do not require cell culture and standard purification
analogy to classic genetic approaches [3–5]. For exam- techniques are rapid and reproducible. The primary
ple, reverse genetics (from gene to phenotype) refers to physiologic role of platelets is to survey the integrity of
the manipulation of a known gene, creation of a cell or the circulatory system and respond rapidly and robustly
organism harboring the genetic mutation or deletion, at sites of vascular injury. In this capacity, platelets un-
and thorough phenotyping of the altered cell or organ- dergo a dramatic phenotypic change in response to a
ism. This strategy is used to determine the role of a large variety of agonists. Manipulations of this vigorous
specific gene in the physiology of a cell or organism. By response by small molecules are readily monitored us-
analogy, reverse chemical genetics is a process whereby ing routine assay systems such as aggregometry to de-
the selectivity of a small molecule for a specific molecu- tect platelet aggregation and luminometry to detect
lar target is established, the small molecule is introduced platelet granule release. Another reason why platelets
into a complex biological system such as an organism are widely used in pharmacologic studies is their impor-
or cell, and the alteration in phenotype is determined tance in human disease. Platelet-mediated arterial
[5]. Forward genetics (from phenotype to gene) is a strat- thrombosis, which causes myocardial and cerebral in-
egy in which complex biological systems are studied farction, is the leading cause of morbidity and mortality
by randomly mutating genes, screening for informative in the industrialized world. Manipulation of platelet func-
phenotypes, and then identifying the gene mutation re- tion using small molecules has proven to be an effective
sponsible for the phenotype of interest. By analogy, means of limiting mortality from acute thrombosis. The
fact that platelets are anucleate, are easy to obtain,
demonstrate a robust response in biological assays, and*Correspondence: rflaumen@bidmc.harvard.edu
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are an important therapeutic target has made them a lets can be drawn into a variety of anticoagulants, as-
sayed in plasma, purified by gel filtration or centrifuga-popular model for studies using small molecules.
The earliest examples of the use of small molecules tion, and resuspended into a variety of buffers. A second
source of variation is the assay conditions. Differentto understand platelet physiology were in the discovery
of platelet agonists. Adenosine diphosphate (ADP) was studies use different concentrations of platelets, differ-
ent concentrations of agonists and inhibitory com-purified as a platelet-activating factor from extracts of
red blood cells based on its ability to cause platelet pounds, static conditions, agitation, or flow. Since com-
pounds that inhibit platelet activation have not beenclumping [6]. Epinephrine was also found to induce
platelet aggregation [7]. Chemists discovered that studied systematically, their activities cannot be directly
compared. What is needed to address these issues isthromboxane A2 activated platelets while investigating
the metabolism of prostaglandin endoperoxides [8]. Sta- a systematic screening strategy of antiplatelet agents
that includes active compounds with unknown targets.ble thromboxane A2 mimetics such as U-46619 have
since been used to study the role of the eicosanoid A Chemical Genetic Analysis of Platelet Activation
In order to enable the discovery of novel signaling path-pathway in platelet activation. Several compounds that
affect signal transduction mechanisms also cause plate- ways in the platelet and to systematize the pharmaco-
logical study of platelet activation, we have used a for-let activation. For example, there is an extensive litera-
ture using Ca2 ionophores such as A23187 to study ward chemical genetic analysis of platelet function. The
three most widely studied and readily assayed plateletthe role of [Ca2]i flux in platelet activation. Phorbol es-
ters have been used widely to evaluate the role of protein functions are granule secretion, aggregation, and shape
change. All three responses can be elicited by a varietykinase C (PKC) in platelet activation. These pharmaco-
logical tools represent only a small fraction of platelet- of agonists and, thus, can be used to study platelet
activation. We chose to screen for compounds that in-activating small molecules that have been used to study
the process of platelet activation. hibited agonist-induced platelet secretion since assays
of granule secretion most readily lend themselves to aInhibitory small molecules have also been used exten-
sively to elucidate mechanisms of platelet activation. high-throughput format. Our cell-based assay evaluates
agonist-induced release of ADP/ATP from platelet gran-Aspirin has been instrumental in defining the role of
cyclooxygenases in platelet activation [9]. Isoform-spe- ules using a luciferin-luciferase detection system.
Blood-banked platelets are used for this assay. Thecific inhibitors of phosphodiesterases (PDE) such as mil-
rinone are also used clinically and have been invaluable assay demonstrates a signal to noise of 63:1 with a
coefficient of variance of 0.14. Approximately 6,000in establishing the role of cAMP in platelet function [10].
Small molecule serine/threonine and tyrosine kinase in- compounds/day can be screened. To date, we have
focused on screening commercially available structur-hibitors, phosphatase inhibitors, lipase inhibitors, cal-
cium chelators, and intracellular protease inhibitors ally characterized drug-like compounds of 500 Da.
The assay has enabled discovery of novel, structurallyhave been used to study platelet signal transduction.
Thrombin receptor antagonists such as RWJ-56110 that distinct inhibitors of platelet activation at a rate of about
0.05% compounds screened. This forward chemical ge-specifically block protease-activated receptor-1 (PAR-1)
have been used to study the role of thrombin-mediated netic analysis of platelet function has lead to the discov-
ery of a large number of structurally distinct, novel inhibi-signaling in platelet activation [11]. Thienopyridine deriv-
atives such as clopidogrel are platelet ADP receptor tors of platelet activation. The great challenge of a
forward chemical genetic analysis of complex biologicalantagonists that are routinely used in the treatment of
thrombotic disorders [12]. Thus, inhibitory small mole- systems, however, is not discovery of novel active com-
pounds. Rather, the challenge lies in the characteriza-cules have been used both as therapeutics and as mo-
lecular probes of platelet function. tion of the compounds.
Characterization of newly discovered small moleculesPerhaps more than in any other cell, signal transduc-
tion in platelets has been defined by small molecules. involves demonstrating the heterogeneity of the com-
pounds, determining whether or not the compounds actYet despite the utility of small molecules in characteriz-
ing platelet activation, there are several limitations with selectively, and identifying the molecular targets of the
compounds. Establishing heterogeneity of the variousthis approach. Inhibitory compounds used to define
platelet activation are selected based on their activity compounds discovered by the high-throughput screen
is an important means of assessing the screen itself. Aagainst known targets. This strategy precludes the dis-
covery of new molecules involved in platelet signaling high-throughput assay of a complex biological system
that identifies compounds that act on a variety of targetspathways. In particular, the strategy of using inhibitory
compounds with known targets excludes the possibility enables interrogation of multiple pathways of the sys-
tem. In contrast, an assay that identifies a group ofof identifying novel platelet-specific targets. Such plate-
let-specific targets are of special interest in the discov- inhibitors directed at a common target will only yield
information about a single aspect of the biological sys-ery of novel antiplatelet agents. Another disadvantage
of the classic pharmacological approach is that it does tem. Thus, it is important to ascertain the functional
heterogeneity of the identified compounds. The valuenot easily provide for a systematic comparison of the
efficacy of large numbers of inhibitors. Typical studies of a small molecule as a molecular probe is directly
proportional to its selectivity. Nonselective compoundsinclude only a few inhibitory compounds. Comparisons
of the results of different studies are complicated by the are of little use in the study of complex biological sys-
tems and need to be eliminated as early as possiblefact that assay conditions vary in significant manners.
One source of variation is the platelet preparation. Plate- in the characterization process from further analysis.
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Figure 1. Characterization of Antiplatelet Compounds Using Chemical Phenotyping
(A) Platelet activation can be stimulated by multiple agonists. Some agonists (SFLLRN, U-46619, epinephrine, and ADP) act via cell surface
receptors that are coupled to G protein-mediated signaling pathways. Collagen stimulates platelets via a cell surface receptor that is coupled
to tyrosine kinase-mediated pathways. Other platelet agonists (PMA and A23187) stimulate platelets by stimulating intermediate signaling
events. Three platelet functions (granule secretion, aggregation, and shape change) can be rapidly assayed using standard procedures.
(B) An active compound identified by high-throughput screening will inhibit activation induced by different agonists and will inhibit different
platelet functions depending on its molecular target. The pattern of inhibition of a particular antiplatelet compound can be used to assess
the mechanism by which the compound inhibits platelet function. Several known platelet inhibitors are presented as examples.
Target identification is the component of a forward gets can be generated and the effect of the small mole-
cule on these candidate molecules can be tested inchemical genetic screen that provides the molecular
understanding of a phenotype. Thus, target identifica- purified systems.
Chemical phenotyping can assess the heterogeneity,tion of diverse and highly selective molecular probes is
the primary goal of such a screen. selectivity, and molecular targets of inhibitory com-
pounds identified by high-throughput screening. Sys-Chemical Phenotyping
In our efforts to characterize antiplatelet compounds tematic comparisons of the inhibitory activity of various
compounds in different assays rapidly demonstrateidentified using our high-throughput screen, we have
used an approach termed chemical phenotyping. Chem- whether they have similar modes of inhibition. In this
manner, heterogeneity is readily established even in theical phenotyping is a method in which the ability of a
small molecule to perturb specific cell functions (out- absence of target identification. Specificity of com-
pounds is also assessed by this method. For example,puts) induced by specific agonists (inputs) is determined
in standard biological assays. The effect of the small if a compound inhibits the activity of two local signaling
networks that are known to be unrelated, then the com-molecule is tested on multiple input-output pairs in order
to isolate the activity of the compound to local signaling pound probably does not act specificity. Alternatively,
the compound may identify a novel crosstalk betweennetworks. A local signaling network is defined as the
subset of molecules required to produce a specific re- two signaling networks that were previously considered
independent. Target identification using chemical phe-sponse following exposure to a particular agonist. Once
sufficiently localized signaling networks affected by an notyping is performed in conjunction with informatics
strategies using widely available structure- and litera-antiplatelet agent are identified, a list of candidate tar-
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Figure 2. Partitioning Signaling Pathways
Using Input-Output Pairs
SFLLRN induces granule secretion via a sig-
naling pathway that includes activation of
PKC and pleckstrin phosphorylation. PMA
induces platelet granule secretion via ac-
tivation of PKC. An inhibitor that blocks
SFLLRN-induced granule secretion is there-
fore tested to determine whether or not it is
able to inhibit PMA-induced granule secre-
tion. If so, then the inhibitor is acting at or
distal to PKC. To determine whether the com-
pound is acting proximally or distally to pleck-
strin phosphorylation, the ability of the com-
pound to inhibit PMA-induced pleckstrin
phosphorylation is determined. If the com-
pound inhibits PMA-induced pleckstrin phos-
phorylation in the platelet, it is tested for its
activity against purified PKC in a platelet-free
assay. Thus, by using systematically designed input-output pairs, increasingly smaller signaling networks can be isolated. Once sufficiently
localized signaling networks are determined, the target of the compound can be identified in a purified protein system.
ture-based search engines. By enabling the generation 1B. If the compound inhibits activation induced by all
agonists and demonstrates no selectivity for a particularof lists of candidate molecules that can be tested in
purified systems, these approaches facilitate the pro- platelet function, then it is most likely a nonspecific
inhibitor. By this method, the selectivity and targets ofcess of target identification.
Chemical Phenotyping of Platelet Activation compounds that act very proximally or distally in a sig-
naling pathway can be determined.Several characteristics render the platelet a good candi-
date for a chemical phenotyping strategy. One, it can be A more challenging task is to interpret patterns of
inhibition that result from compounds that interrupt in-activated by different agonists that act through distinct
cellular receptors (Figure 1A). Two, it has several rela- termediate signaling events. The tendency of signaling
pathways to diverge, loop, and converge diminishes thetively distinct functional outputs (e.g., granule secretion,
aggregation, and shape change). Three, agonist expo- likelihood that inhibition by compounds that affect inter-
mediate signaling events will yield simple horizontal orsure results in robust signals that are easily detected in
functional assays. Four, the signaling pathways leading vertical patterns of inhibition. The fact that both the
functional activity and targets of many inhibitors ofto platelet activation have been described in detail.
These characteristics are not unique to platelets and platelet activation have previously been identified, how-
ever, enables pattern analysis as a means to character-the chemical phenotyping strategy could be applied to
a forward chemical genetic analysis of a wide variety of ize the mechanism of an unknown inhibitor. If pattern
analysis suggests a specific signaling network, thencomplex biological systems. The platelet serves as an
example of this strategy. more refined functional assays can be used to assess
the hypothesis. For example, we have identified severalRecognizing phenotypic patterns. The initial evalua-
tion of a novel inhibitor of platelet activation by chemical compounds that inhibit phosphodiesterases based on
the pattern of inhibition compared with well-studiedphenotyping uses platelet agonists in order to stimulate
readily quantified responses. The proximal signaling phosphodiesterase inhibitors such as milrinone (Figure
1B). Novel antiplatelet agents that demonstrated theevents of each agonist are well described. If a small
molecule inhibits platelet activation induced by only one same pattern of inhibitory activity as milrinone were
tested for their effect on agonist-induced cAMP levels.of the agonists, then the compound is acting at or near
the receptor for that agonist. Furthermore, the com- These compounds caused increased agonist-induced
cAMP levels and were subsequently found to inhibitpound will inhibit every platelet function induced by that
agonist. For example, the thrombin receptor antagonist phosphodiesterase in assays of purified proteins. The
availability of purified and/or recombinant proteins andRWJ-56110 will inhibit activation of all platelet functions
induced by the thrombin receptor agonist peptide a wide variety of enzyme assays that are offered on a
fee for service basis by several commercial vendorsSFLLRN but will not inhibit activation induced by any
other agonists [13]. Thus, the pattern of inhibition of a render this approach feasible.
Input-Ouput Pairs. When the patterns of inhibition failscompound that acts specifically on a proximal receptor
will be horizontal in the matrix depicted in Figure 1B. A to suggest a target, then more detailed assays are re-
quired. The goal of these assays is to partition signalingcompound may also act distally in a signaling cascade,
inhibiting activation of only one platelet function. For pathways into progressively more localized signaling
networks (Figure 2) and determine which of the localizedexample, cytochalasin D will inhibit platelet shape
change without inhibition of platelet granule secretion signaling networks is affected by the compound of inter-
est. Just as importantly, these assays will identify as-or platelet aggregation [14]. Cytochalasin D will inhibit
shape induced by any agonist. Thus, the pattern of inhi- pects of signaling cascades in which the compound
has no activity. Assays that are perturbed by the smallbition of compounds that inhibit distal events in platelet
signaling will be vertical in the matrix shown in Figure molecule will provide target information. Assays that are
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Figure 3. A Generalized Approach to Chemical Phenotyping
Small molecules that inhibit platelet activation induced by specific agonist(s) are tested in a series of assays. The ability of the compound to
inhibit platelet functions (yellow boxes) induced by the specific agonist(s) is determined. If the inhibitor does inhibit in the specific assay and
a list of candidate targets can be generated based on its activity (categories of candidate molecules are shown in the green boxes), then it
is tested against purified target candidates (red box). If the compound shows no activity in the specific assay or it shows no activity against
the purified candidate targets, then it is tested in an assay that interrogates a different signaling network. This process is repeated until a
local signaling network that includes the candidate target is identified.
not perturbed by the small molecule will provide informa- ing networks requires detailed knowledge of signaling
pathways of a particular system. In addition, this ap-tion regarding specificity. This strategy begins with the
identification of an input-output pair that is inhibited by proach puts a premium on the availability of agonists
that function via specific signaling molecules (i.e., PMAthe compound. For example, we have screened for com-
pounds that inhibit granule secretion induced by the and Ca2 ionophore). If these prerequisites are met, this
chemical phenotyping strategy can enable investigatorsthrombin receptor agonist peptide, SFLLRN. Several of
the signaling molecules involved in SFLLRN-induced to focus their target identification efforts to a limited
number of candidate proteins. This strategy also facili-granule secretion have been identified. We can therefore
use an agonist that stimulates secretion via a signaling tates identification of compounds that act nonspecifi-
cally (i.e., compounds that inhibit multiple unrelated lo-molecule distal to the thrombin receptor, PAR-1, and
determine whether our compound also inhibits activa- calized signaling networks).
Lack of adequate input-output pairs may precludetion induced by this agonist. For example, phorbol 12-
myristate 13-acetate (PMA) stimulates platelet secretion identification of the target of a compound or even its
localized signaling network. Thus, more general ap-via its interaction with PKC. Inhibition of PMA-induced
granule secretion by the small molecule indicates that proaches may be required. Our generalized approach
involves assaying an active compound for its ability toit inhibits either PKC or signaling molecules distal to
PKC involved in granule secretion (Figure 2). In this case, inhibit agonist-induced second messenger systems and
interfere with posttranslational modifications. A sche-we would refine the input-output pair. For example, we
could evaluate whether the small molecule inhibits PMA- matic of this approach is presented in Figure 3. Initial
assays are designed to determine the effects of theinduced pleckstrin phosphorylation. If so, then we would
determine whether the compound inhibits the activity inhibitory compound on agonist-induced cAMP and cGMP
levels. Cyclic nucleotides are assessed in initial testingof purified PKC. If the small molecule fails to inhibit PKC-
induced granule release, we would evaluate its ability because their levels can be assayed using routine meth-
ods and their influence on platelet activity is global.to inhibit signaling pathways proximal to PKC, such as
SFLLRN-induced diacylglycerol production. The ap- Thus, compounds that perturb cyclic nucleotide levels
will affect multiple signaling pathways. Compounds thatproach of identifying progressively smaller local signal-
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affect agonist-induced [Ca2]i flux also demonstrate active compounds. Extensive systematic phenotyping
enables rapid identification of compounds that act non-global effects on platelet function. Agonist-induced
[Ca2]i flux in platelets is readily assayed by standard specifically, thus instructing the elimination of nonspe-
cific molecules from further analysis. This approach alsomethods. Thus, compounds that do not affect agonist-
induced cyclic nucleotide metabolism are analyzed for allows identification of compounds with particularly in-
teresting or novel activities. This ability to rapidly priori-effects on agonist-induced [Ca2]i flux. The most well-
characterized posttranslational modification that we tize compounds for further evaluation is a significant
asset in performing chemical genetic analyses. If thescreen for is phosphorylation. Immunoblots of platelet
proteins separated by two-dimensional electrophoresis biological system is reasonably well characterized, then
this approach will facilitate the generation of lists ofprobed with anti-phosphoserine/phosphothreonine or
anti-phosphotyrosine antibodies provide a global as- candidate compounds in order to identify the compound
target. This biological approach to characterization ofsessment of the effect of the compound on kinase activ-
ity. Using mass spectroscopy, it may be possible to compounds has limitations. The strategy cannot identify
novel targets. It can only characterize novel activities.identify specific substrates of affected kinases. Such
identification will facilitate the generation of a list of Once a compound that demonstrates a novel activity is
identified, its target will need to be purified by alternativecandidate proteins. Lipid-derived second messengers
play an essential role in platelet activation. If no effects strategies. In addition, proof of specificity is limited to
the particular assays and system in which it is studied.of the inhibitory compound are observed in the assays
above or if assays of purified proteins fail to reveal tar- Nonetheless, our experience with a chemical genetic
analysis of platelet activation demonstrates that care-gets, then the effects of the compounds on agonist-
induced phospholipid metabolism are evaluated. More fully designed biological assays can go a long way to
realizing the promise of molecular dissection of complexspecialized studies can be performed in a collaborative
basis in laboratories in which these techniques are rou- biological systems using small molecules.
tine since the small molecules are convenient to trans-
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The strategy of using a series of biological assays to
characterize the mechanism of action of an inhibitory
compound is not limited to studies of platelets or signal
transduction. Any complex biological system that can
be divided into smaller input-output pairs is a candidate
for such an approach. Indeed, the activity of small mole-
cules in biological assays has been used for decades
to facilitate the identification of molecular targets of
